Sam Waksal
Sam Waksal
Samuel D. "Sam" Waksal, Ph.D.,is the founder and former CEO of the biopharmaceutical company ImClone Systems. He is also the founder and Chief of Innovation, Science and Strategy of Kadmon Pharmaceuticals which was financed with private capital and commenced operations in New York City in 2010. At ImClone, Waksal led the company to develop the landmark cancer drug Erbitux. During the course of its review process with Food and Drug AdministrationWaksal became involved in an insider trading scandal revolving around...
cancer damaged events including realize seriously
I realize that the events of 2001 have seriously damaged our credibility with many of our constituents, including cancer patients, oncologists, and you, our investors.